These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32864597)

  • 1. Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial.
    Kovatchev BP; Kollar L; Anderson SM; Barnett C; Breton MD; Carr K; Gildersleeve R; Oliveri MC; Wakeman CA; Brown SA
    Lancet Digit Health; 2020 Feb; 2(2):e64-e73. PubMed ID: 32864597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Controlled Trial of Mobile Closed-Loop Control.
    Kovatchev B; Anderson SM; Raghinaru D; Kudva YC; Laffel LM; Levy C; Pinsker JE; Wadwa RP; Buckingham B; Doyle FJ; Brown SA; Church MM; Dadlani V; Dassau E; Ekhlaspour L; Forlenza GP; Isganaitis E; Lam DW; Lum J; Beck RW;
    Diabetes Care; 2020 Mar; 43(3):607-615. PubMed ID: 31937608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.
    Brown SA; Breton MD; Anderson SM; Kollar L; Keith-Hynes P; Levy CJ; Lam DW; Levister C; Baysal N; Kudva YC; Basu A; Dadlani V; Hinshaw L; McCrady-Spitzer S; Bruttomesso D; Visentin R; Galasso S; Del Favero S; Leal Y; Boscari F; Avogaro A; Cobelli C; Kovatchev BP
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3674-3682. PubMed ID: 28666360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.
    McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ
    Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial.
    Isganaitis E; Raghinaru D; Ambler-Osborn L; Pinsker JE; Buckingham BA; Wadwa RP; Ekhlaspour L; Kudva YC; Levy CJ; Forlenza GP; Beck RW; Kollman C; Lum JW; Brown SA; Laffel LM;
    Diabetes Technol Ther; 2021 May; 23(5):342-349. PubMed ID: 33216667
    [No Abstract]   [Full Text] [Related]  

  • 9. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
    Hovorka R; Kumareswaran K; Harris J; Allen JM; Elleri D; Xing D; Kollman C; Nodale M; Murphy HR; Dunger DB; Amiel SA; Heller SR; Wilinska ME; Evans ML
    BMJ; 2011 Apr; 342():d1855. PubMed ID: 21493665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
    Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study.
    Sharifi A; De Bock MI; Jayawardene D; Loh MM; Horsburgh JC; Berthold CL; Paramalingam N; Bach LA; Colman PG; Davis EA; Grosman B; Hendrieckx C; Jenkins AJ; Kumareswaran K; Kurtz N; Kyoong A; MacIsaac RJ; Speight J; Trawley S; Ward GM; Roy A; Jones TW; O'Neal DN
    Diabetes Technol Ther; 2016 Dec; 18(12):772-783. PubMed ID: 27835037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.
    Boughton CK; Hartnell S; Thabit H; Mubita WM; Draxlbauer K; Poettler T; Wilinska ME; Hood KK; Mader JK; Narendran P; Leelarathna L; Evans ML; Hovorka R
    Lancet Healthy Longev; 2022 Mar; 3(3):e135-e142. PubMed ID: 35359882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial.
    O'Malley G; Messer LH; Levy CJ; Pinsker JE; Forlenza GP; Isganaitis E; Kudva YC; Ekhlaspour L; Raghinaru D; Lum J; Brown SA;
    Diabetes Technol Ther; 2021 Apr; 23(4):245-252. PubMed ID: 33155824
    [No Abstract]   [Full Text] [Related]  

  • 14. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multinational Home Use of Closed-Loop Control Is Safe and Effective.
    Anderson SM; Raghinaru D; Pinsker JE; Boscari F; Renard E; Buckingham BA; Nimri R; Doyle FJ; Brown SA; Keith-Hynes P; Breton MD; Chernavvsky D; Bevier WC; Bradley PK; Bruttomesso D; Del Favero S; Calore R; Cobelli C; Avogaro A; Farret A; Place J; Ly TT; Shanmugham S; Phillip M; Dassau E; Dasanayake IS; Kollman C; Lum JW; Beck RW; Kovatchev B;
    Diabetes Care; 2016 Jul; 39(7):1143-50. PubMed ID: 27208316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.
    Renard E; Farret A; Kropff J; Bruttomesso D; Messori M; Place J; Visentin R; Calore R; Toffanin C; Di Palma F; Lanzola G; Magni P; Boscari F; Galasso S; Avogaro A; Keith-Hynes P; Kovatchev B; Del Favero S; Cobelli C; Magni L; DeVries JH;
    Diabetes Care; 2016 Jul; 39(7):1151-60. PubMed ID: 27208331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
    Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol.
    Leelarathna L; Dellweg S; Mader JK; Barnard K; Benesch C; Ellmerer M; Heinemann L; Kojzar H; Thabit H; Wilinska ME; Wysocki T; Pieber TR; Arnolds S; Evans ML; Hovorka R;
    BMJ Open; 2014 Sep; 4(9):e006075. PubMed ID: 25186158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multinight "bedside" closed-loop control for patients with type 1 diabetes.
    Brown SA; Kovatchev BP; Breton MD; Anderson SM; Keith-Hynes P; Patek SD; Jiang B; Ben Brahim N; Vereshchetin P; Bruttomesso D; Avogaro A; Del Favero S; Boscari F; Galasso S; Visentin R; Monaro M; Cobelli C
    Diabetes Technol Ther; 2015 Mar; 17(3):203-9. PubMed ID: 25594434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.